Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation (2017 - 2025)

Historic Accumulated Depreciation for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q2 2025 value amounting to $9.6 million.

  • Crinetics Pharmaceuticals' Accumulated Depreciation rose 5384.37% to $9.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $9.6 million, marking a year-over-year increase of 5384.37%. This contributed to the annual value of $7.7 million for FY2024, which is 5256.51% up from last year.
  • Crinetics Pharmaceuticals' Accumulated Depreciation amounted to $9.6 million in Q2 2025, which was up 5384.37% from $8.6 million recorded in Q1 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Accumulated Depreciation ranged from a high of $9.6 million in Q2 2025 and a low of $2.8 million during Q1 2021
  • Over the past 5 years, Crinetics Pharmaceuticals' median Accumulated Depreciation value was $4.6 million (recorded in 2023), while the average stood at $5.2 million.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Accumulated Depreciation soared by 1695.04% in 2023 and then surged by 5772.18% in 2025.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Accumulated Depreciation stood at $3.5 million in 2021, then increased by 17.36% to $4.1 million in 2022, then increased by 24.09% to $5.1 million in 2023, then soared by 52.57% to $7.7 million in 2024, then rose by 23.98% to $9.6 million in 2025.
  • Its Accumulated Depreciation stands at $9.6 million for Q2 2025, versus $8.6 million for Q1 2025 and $7.7 million for Q4 2024.